TransCode Therapeutics Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics Inc. (NASDAQ:RNAZ) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 34,446 shares, a drop of 34.8% from the June 30th total of 52,823 shares. Based on an average daily volume of 41,287 shares, the short-interest ratio is currently 0.8 days. Currently, 3.3% of the company’s shares are short sold.

TransCode Therapeutics Price Performance

RNAZ stock opened at $4.56 on Friday. The firm has a market capitalization of $4.83 million, a P/E ratio of -0.09 and a beta of 1.23. The business’s 50-day moving average is $6.31 and its two-hundred day moving average is $7.99. TransCode Therapeutics has a 1 year low of $3.82 and a 1 year high of $20.99.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings data on Friday, May 15th. The company reported ($21.28) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, TransCode Therapeutics has a consensus rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.